DSIP Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion

Delta sleep-inducing peptide (DSIP) is a nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. Its molecular formula is C35H48N10O15 and its molecular weight is 848.8 Da (PubChem CID 68816). Understanding its pharmacokinetics requires separating two distinct compartments: peripheral plasma, where the free peptide is subject to rapid enzymatic clearance, and the CNS compartment, where transport mechanisms and local metabolic enzymes govern availability.

Research on DSIP pharmacokinetics spans roughly four decades and employs radioimmunoassay (RIA), radiolabeled tracer studies, HPLC, and cell culture BBB models. All published data derive from preclinical animal models and in vitro systems; no formal clinical pharmacokinetic trials have been registered on ClinicalTrials.gov as of April 2026.

Absorption

Intravenous Administration

IV injection provides immediate, complete systemic availability and has been the primary route in pharmacokinetic studies. Dogs receiving IV DSIP or its analogs showed rapid peptide appearance in both plasma and CSF (PMID 3768731). The plasma concentration-time profile following IV dosing reflects distribution and elimination phases, with the elimination governed primarily by enzymatic degradation rather than renal filtration of intact peptide.

Subcutaneous Administration

Subcutaneous administration produces biological effects in vivo. A controlled study in cats (n = 8) using 120 nmol/kg DSIP administered subcutaneously demonstrated significant increases in deep slow-wave sleep over 8 hours of polygraphic recording (PMID 3671519). This confirms that intact or biologically active fragments reach the CNS following peripheral subcutaneous injection. Quantitative bioavailability data (F%) from SC versus IV comparisons have not been published in peer-reviewed literature.

Oral Administration

Oral bioavailability of DSIP as an intact nonapeptide is expected to be low, consistent with the general vulnerability of unmodified peptides to gastrointestinal proteolysis. Schoenenberger (1984) noted that unweaned rats are capable of intestinal uptake of DSIP, suggesting an age-dependent, possibly paracellular or endocytic, absorption mechanism in immature intestinal epithelium (PMID 6548966). No oral bioavailability fraction has been established in adult animals.

Transdermal/Iontophoretic Delivery

Iontophoretic delivery of DSIP across human skin was investigated as a model system for peptide drug delivery (PMID 9876605). DSIP was stable across a pH range of 4-9 in buffer. However, skin enzymes, predominantly metalloproteases, cleaved the peptide during transdermal delivery. Metalloprotease inhibitors such as o-phenanthroline significantly enhanced penetration flux; at pH 4 with 0.2 mM o-phenanthroline, flux increased approximately eightfold compared to uninhibited controls. This work established that skin metalloprotease activity is the principal barrier to transdermal DSIP delivery, not membrane impermeability per se.

Conjunctival Route

A study by Badikov et al. (1990) examined distribution of radiolabeled amino acids and DSIP following conjunctival instillation in rats, identifying systemic distribution pathways accessible via the ocular route (PMID 2268701). Quantitative data on this route are limited.

Distribution

Blood-Brain Barrier Permeability

DSIP CNS access has been studied with three independent experimental approaches, yielding complementary data.

In vitro BBB model (PMID 2576448). Raeissi and Audus (1989) used primary bovine brain microvessel endothelial cell (BMEC) monolayers mounted in a side-by-side diffusion apparatus. Key findings:

• Transendothelial DSIP flux was linear with time and with concentration, establishing non-saturable, passive diffusion as the dominant mechanism.
• The apparent permeability coefficient was comparable to water-soluble, low-permeability reference compounds such as fluorescein.
• Flux was bidirectional, insensitive to metabolic inhibitors, and unaffected by excess tryptophan, ruling out carrier-mediated transport in the abluminal-to-luminal direction.
• Apparent t1/2 for DSIP degradation to tryptophan and des-Trp-DSIP was approximately 10 hours under these cell culture conditions.

Blood-CSF barrier (PMID 3420012). Zlokovic et al. (1988) studied unidirectional flux of 125I-labeled DSIP using perfused sheep choroid plexuses. Results:

• Choroid epithelium showed low-to-moderate permeability to intact DSIP from the blood side.
• A saturable transport mechanism with Michaelis-Menten kinetics was identified: Kt approximately 5.0 +/- 0.4 nM; Vmax approximately 272 +/- 10 fmol/min.
• No significant outward flux of intact peptide from the CSF compartment was detected, indicating that DSIP lacks the active removal mechanism present for amino acids and several other peptides at this barrier.

In vivo CSF sampling (PMID 3768731). Banks, Kastin, and Coy (1986) measured plasma and CSF concentrations simultaneously in dogs after IV injection of DSIP or four analogs. Increase in CSF peptide concentration correlated significantly with plasma concentration (p < 0.05), plasma half-life (p < 0.05), and peptide lipophilicity (p < 0.05), but not with molecular weight or plasma protein binding. A combined multivariate model incorporating all three correlated parameters yielded r = 0.813 (p < 0.00005), explaining most of the variance in CSF entry across analogs.

The collective data indicate that DSIP crosses the BBB primarily by passive diffusion, with CSF entry amplified by longer plasma half-life (more time for diffusion) and higher lipophilicity. A saturable, high-affinity/low-capacity transport mechanism exists at the choroid plexus but does not contribute a large absolute flux.

flowchart TD
    A["IV / SC Administration\nIntact DSIP in plasma"] --> B["BBB Passive Diffusion\n(non-saturable, bidirectional)\nPMID 2576448"]
    A --> C["Blood-CSF Barrier\nChoroid Plexus\nSaturable transport\nKt ~5.0 nM, Vmax ~272 fmol/min\nPMID 3420012"]
    B --> D["CNS Interstitial Fluid / Parenchyma"]
    C --> D
    D --> E["Local aminopeptidase\ncleavage: N-terminal Trp\nt1/2 ~15 min brain homogenate\nPMID 6548966"]
    D --> F["Released from\nsynaptosomes on\ndepolarization\nPMID 8474631"]
    A --> G["Peripheral Tissue Distribution\n86–849 pg/mg across 12 organ types\nLargely protein-bound macroforms\nPMID 6548030"]
    A --> H["Plasma Enzymatic Degradation\nAminopeptidases (N-terminal)\nPeptidyl dipeptidase A (C-terminal)\nPMID 7763273"]

Tissue Distribution

Radioimmunoassay of 12 peripheral tissues from rats (PMID 6548030) found immunoreactive DSIP-like material ranging from 86 pg/mg in muscle to 849 pg/mg in stomach. The material in peripheral organs resolved as large molecular weight forms on Sephadex G-15 and G-25 gel filtration, substantially larger than the 848.8 Da nonapeptide. Tryptic digestion released small immunoreactive fragments with minimal loss of total immunoreactivity, consistent with DSIP bound to larger carrier proteins or existing as a propeptide precursor. Dissociation to small forms occurred at lower tissue concentrations.

Brain distribution was mapped by immunofluorescence in rabbit brain tissue (PMID 3135926). Immunoreactive material was found in multiple CNS regions. Immunoreactive DSIP-like material has also been detected in human plasma, urine, CSF, and milk, with endogenous material in these fluids reported to exist in protein-bound, protease-protected form (PMID 6548966).

Plasma Protein Binding

In the Banks et al. (1986) dog study (PMID 3768731), the degree of plasma protein binding did not correlate with CSF entry across DSIP analogs. This suggests that plasma protein binding is not a dominant pharmacokinetic determinant for CNS distribution at the concentrations studied.

Volume of Distribution

No formal Vd has been reported from compartmental modeling of DSIP kinetics. The wide tissue distribution data (PMID 6548030) and the presence of endogenous DSIP-like material across multiple organ systems suggests a large apparent Vd, but this parameter has not been calculated in a published pharmacokinetic study.

Metabolism

DSIP undergoes proteolytic degradation by at least two distinct enzymatic pathways that act at opposite termini of the nonapeptide.

N-Terminal Aminopeptidase Pathway

Brain membrane preparations degrade DSIP with liberation of tryptophan from the N-terminus. Nakamura et al. (1993) (PMID 8474631) identified a puromycin-sensitive aminopeptidase as the responsible enzyme in rat brain membrane fractions. Bestatin, a broad aminopeptidase inhibitor, also significantly inhibited DSIP degradation and tryptophan release. The half-life for this N-terminal tryptophan cleavage by brain slices and homogenates is approximately 15 minutes (PMID 6548966), making this the most rapid metabolic pathway identified.

C-Terminal Peptidyl Dipeptidase A (ACE) Pathway

Augustijns et al. (1995) (PMID 7763273) demonstrated that peptidyl dipeptidase A (angiotensin-converting enzyme, ACE) in bovine brain microvessel endothelial cells sequentially removes dipeptides and tripeptides from the C-terminus of DSIP. Both dipeptidase and tripeptidase activity of this enzyme contribute. Full stabilization of DSIP against BBMEC metabolism required co-administration of both captopril (peptidyl dipeptidase A inhibitor) and bestatin (aminopeptidase inhibitor), confirming that both pathways operate simultaneously at the BBB.

Skin Metalloprotease Pathway

During iontophoretic delivery through excised skin, DSIP was cleaved primarily by metalloproteases rather than serine or cysteine proteases (PMID 9876605). EDTA, o-phenanthroline, dilucine, and sodium deoxycholate each partially inhibited skin-enzyme degradation, with o-phenanthroline showing the greatest protective effect. This metalloprotease vulnerability is relevant to transdermal delivery strategies but may not be a primary metabolic route following injection.

Metabolic Stability Modifiers

The isoaspartyl residue in position 5 (Asp in native DSIP can form isoaspartate under certain conditions) was examined in the context of carboxypeptidase-Y-mediated fragmentation of isoaspartyl peptides (PMID 2140948). This represents a potential additional degradation route under conditions where Asp undergoes succinimide-mediated isomerization, though the in vivo relevance at physiological conditions has not been established.

Endogenous Plasma Protection

Endogenous immunoreactive DSIP-like material in plasma and other biological fluids is reported in protein-bound form (PMID 6548966), a configuration that would reduce enzymatic accessibility and substantially extend effective half-life compared to free synthetic peptide administered exogenously.

Excretion

No formal renal or biliary excretion studies for DSIP or its metabolites have been published in the peer-reviewed literature. The principal fate of systemically administered DSIP is presumed to be proteolytic degradation to constituent amino acids, which then enter normal amino acid metabolic pools. Immunoreactive DSIP-like material has been detected in human urine (PMID 6548966), indicating either renal filtration of intact peptide or a fragment retaining the immunoreactive epitope. Quantitative urinary recovery data are unavailable.

Summary of Pharmacokinetic Parameters

Phosphorylated Analog: DSIP-P

Schoenenberger (1984) reported the synthesis of phospho-DSIP (DSIP-P), a derivative phosphorylated at the serine in position 7, described as substantially more potent than native DSIP (PMID 6548966). Both DSIP and DSIP-P occur in human CSF. The phosphorylated form is expected to have altered metabolic stability and potentially different BBB permeability due to the charged phosphate group; however, detailed ADME data for DSIP-P as a standalone compound have not been published.

Research Gaps

The published DSIP pharmacokinetic literature is substantial for in vitro and animal work but has important gaps:

1. No compartmental modeling. Formal two- or three-compartment models with estimated Vd, clearance, AUC, and bioavailability fractions have not been published.
2. No human PK data. Despite clinical research on DSIP for insomnia and opioid withdrawal (PMID 9617990), no published study reports quantitative human plasma or CSF pharmacokinetics.
3. No intranasal data. Intranasal delivery, which bypasses first-pass BBB metabolism and may exploit olfactory transport, has not been characterized for DSIP.
4. Endogenous carrier unclear. The large protein-bound form of DSIP in peripheral tissues and plasma (PMID 6548030) has not been fully characterized. Whether it represents a specific binding protein or non-specific plasma protein association affects interpretation of endogenous versus exogenous peptide kinetics.

These gaps mean that DSIP pharmacokinetics remain incompletely characterized relative to modern peptide therapeutics, and all quantitative parameters cited here carry preclinical, primarily in vitro or animal-model, caveats.

See also

More on Dsip:

• Dsip research overview
• Dsip: Mechanism of action
• Dsip: Clinical & preclinical evidence
• Dsip: Safety profile
• Dsip: Dose-response

Related peptide family:

• Nootropic Peptides

Pathway context:

• Neuropeptides & Cognitive Function

Head-to-head comparisons:

• Dsip vs GHK-Cu
• Selank vs Dsip
• Semax vs Dsip